🍬 Type 1 Diabetes Mellitus (T1DM)


1. Definition

  • Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune disorder characterized by the destruction of pancreatic beta cells, leading to absolute insulin deficiency.
  • It results in hyperglycemia, requiring lifelong insulin therapy.
  • T1DM is the most common form of diabetes in children and adolescents.

2. Causes

  • Autoimmune destruction of insulin-producing beta cells in the islets of Langerhans
  • Genetic predisposition with environmental triggers
  • Associated autoimmune conditions (e.g., celiac disease, autoimmune thyroiditis)

3. Risk Factors

  • Family history of T1DM
  • Genetic markers: HLA-DR3, HLA-DR4
  • Viral infections (e.g., Coxsackie B, enteroviruses)
  • Early cow’s milk exposure (possible)
  • Other autoimmune diseases (e.g., Hashimoto's, Addison’s)

4. Types

Type Description
Type 1A (autoimmune) Positive for autoantibodies (e.g., anti-GAD, IA2)
Type 1B (idiopathic) No detectable autoantibodies
Latent Autoimmune Diabetes in Adults (LADA) Milder, slower-onset autoimmune diabetes in adults

5. Pathogenesis

  • Autoimmune attack on beta cells → ↓ insulin production → ↑ blood glucose
  • Without insulin:
    • Glucose cannot enter cells → energy deficit → lipolysis
    • Ketone body production → metabolic acidosis → diabetic ketoacidosis (DKA)
  • Hyperglycemia → osmotic diuresis → dehydration, electrolyte loss

6. Clinical Presentation

Symptoms

  • Polyuria
  • Polydipsia
  • Weight loss
  • Fatigue
  • Nocturia/bedwetting
  • Blurred vision

Signs

  • Dehydration (dry mucous membranes, tachycardia)
  • Kussmaul breathing (if DKA)
  • Fruity-smelling breath (ketones)
  • Lethargy or altered consciousness (if severe)

Physical Examination Findings

  • Low weight/BMI
  • Delayed growth/puberty
  • Possible acanthosis nigricans (if insulin resistance overlaps)

7. Organ & System Complications

System Complications
Metabolic Diabetic ketoacidosis (DKA), hypoglycemia
Renal Microalbuminuria → diabetic nephropathy
Ophthalmologic Retinopathy, cataracts
Neurologic Peripheral neuropathy, autonomic dysfunction
Cardiovascular Early atherosclerosis, hypertension
Psychosocial Eating disorders, anxiety, school difficulties

8. Diagnostic Investigations

Test Reason
Blood glucose (random) ≥11.1 mmol/L with symptoms confirms diagnosis
Fasting glucose ≥7.0 mmol/L
HbA1c ≥6.5% (48 mmol/mol)
Urine ketones/glucose Suggests ketosis and glycosuria
Blood gas, serum ketones For DKA assessment

9. Other Relevant Investigations

Test Reason
Autoantibodies (anti-GAD, IA2, ZnT8) Confirm autoimmune type
C-peptide Reflects endogenous insulin production
Thyroid function tests Screen for autoimmune thyroiditis
TTG-IgA Screen for celiac disease
Lipid profile Baseline cardiovascular risk

10. Treatment

Curative/Definitive

  • No cure; requires lifelong insulin therapy

Empirical

  • Start insulin therapy immediately after diagnosis

Supportive

  • Insulin regimen: basal-bolus or pump
  • Blood glucose monitoring (fingerstick or CGM)
  • Carbohydrate counting and dietary education
  • Sick day management
  • Family and school support

Palliative

  • In cases of severe complications, end-of-life care may be discussed

11. Long-Term Complications of Treatment

Treatment Complication Monitoring Expected Results
Insulin therapy Hypoglycemia, lipodystrophy, weight gain SMBG/CGM, injection site rotation, BMI Stable glucose, HbA1c <7.5%, minimal hypo
Poor compliance DKA, hyperglycemia, long-term complications HbA1c every 3 months, ketone testing HbA1c <7.5%, no DKA episodes

12. Surveillance for the Disease

Domain Frequency What to Monitor
HbA1c Every 3 months Target <7.5%
Growth & puberty Every 3–6 months Height, weight, Tanner staging
Renal Yearly from age 10 or 5 years after diagnosis Urine albumin:creatinine ratio
Eyes Yearly from age 12 Retinal exam (retinopathy screening)
Thyroid function Yearly TSH, free T4
Celiac screening Every 1–2 years TTG-IgA, total IgA
Lipids At puberty, then every 5 years Fasting lipid profile
Mental health As needed Mood, anxiety, eating disorder screening

13. Malaysia Support Group for Parents

Support Group Description Contact/Link
Diabetes Malaysia Advocacy, awareness, peer support www.diabetes.org.my
MySihat (Health Promotion Board) Educational materials and family resources www.mysihat.gov.my
Hospital-based diabetes clinics Dietitian, endocrinologist, diabetic educator Available at HKL, HUSM, UMMC, Penang GH, etc.
Facebook groups (e.g. T1DM Malaysia) Parent and adolescent peer-to-peer support Search “Type 1 Diabetes Malaysia” on Facebook